These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29562505)

  • 1. Voxel-Based Acetylcholinesterase PET Study in Early and Late Onset Alzheimer's Disease.
    Hirano S; Shinotoh H; Shimada H; Ota T; Sato K; Tanaka N; Zhang MR; Higuchi M; Fukushi K; Irie T; Kuwabara S; Suhara T
    J Alzheimers Dis; 2018; 62(4):1539-1548. PubMed ID: 29562505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dementia with Lewy bodies can be well-differentiated from Alzheimer's disease by measurement of brain acetylcholinesterase activity-a [11C]MP4A PET study.
    Shimada H; Hirano S; Sinotoh H; Ota T; Tanaka N; Sato K; Yamada M; Fukushi K; Irie T; Zhang MR; Higuchi M; Kuwabara S; Suhara T
    Int J Geriatr Psychiatry; 2015 Nov; 30(11):1105-13. PubMed ID: 26280153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling.
    Nagatsuka Si S; Fukushi K; Shinotoh H; Namba H; Iyo M; Tanaka N; Aotsuka A; Ota T; Tanada S; Irie T
    J Cereb Blood Flow Metab; 2001 Nov; 21(11):1354-66. PubMed ID: 11702050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[(11)C]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for Alzheimer's disease.
    Tanaka N; Fukushi K; Shinotoh H; Nagatsuka S; Namba H; Iyo M; Aotsuka A; Ota T; Tanada S; Irie T
    J Cereb Blood Flow Metab; 2001 Mar; 21(3):295-306. PubMed ID: 11295884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple method for the detection of abnormal brain regions in Alzheimer's disease patients using [11C]MP4A: comparison with [123I]IMP SPECT.
    Ota T; Shinotoh H; Fukushi K; Nagatsuka S; Namba H; Iyo M; Aotsuka A; Tanaka N; Sato K; Shiraishi T; Tanada S; Arai H; Irie T
    Ann Nucl Med; 2004 May; 18(3):187-93. PubMed ID: 15233279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD.
    Richter N; Nellessen N; Dronse J; Dillen K; Jacobs HIL; Langen KJ; Dietlein M; Kracht L; Neumaier B; Fink GR; Kukolja J; Onur OA
    Neuroimage Clin; 2019; 24():101978. PubMed ID: 31422337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer's disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis.
    Marcone A; Garibotto V; Moresco RM; Florea I; Panzacchi A; Carpinelli A; Virta JR; Tettamanti M; Borroni B; Padovani A; Bertoldo A; Herholz K; Rinne JO; Cappa SF; Perani D
    J Alzheimers Dis; 2012; 31(2):387-99. PubMed ID: 22596267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography: quantitative measurement of brain acetylcholinesterase activity using radiolabeled substrates.
    Namba H; Fukushi K; Nagatsuka S; Iyo M; Shinotoh H; Tanada S; Irie T
    Methods; 2002 Jul; 27(3):242-50. PubMed ID: 12183113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease.
    Irie T; Fukushi K; Namba H; Iyo M; Tamagami H; Nagatsuka S; Ikota N
    J Nucl Med; 1996 Apr; 37(4):649-55. PubMed ID: 8691261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid deposition in early onset versus late onset Alzheimer's disease.
    Cho H; Seo SW; Kim JH; Suh MK; Lee JH; Choe YS; Lee KH; Kim JS; Kim GH; Noh Y; Ye BS; Kim HJ; Yoon CW; Chin J; Na DL
    J Alzheimers Dis; 2013; 35(4):813-21. PubMed ID: 23507771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease.
    Iyo M; Namba H; Fukushi K; Shinotoh H; Nagatsuka S; Suhara T; Sudo Y; Suzuki K; Irie T
    Lancet; 1997 Jun; 349(9068):1805-9. PubMed ID: 9269216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer's disease.
    Tondo G; Iaccarino L; Caminiti SP; Presotto L; Santangelo R; Iannaccone S; Magnani G; Perani D
    Alzheimers Res Ther; 2020 Apr; 12(1):50. PubMed ID: 32354345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease.
    Rinne JO; Kaasinen V; Järvenpää T; Någren K; Roivainen A; Yu M; Oikonen V; Kurki T
    J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):113-5. PubMed ID: 12486280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic activity correlates with reserve proxies in Alzheimer's disease.
    Garibotto V; Tettamanti M; Marcone A; Florea I; Panzacchi A; Moresco R; Virta JR; Rinne J; Cappa SF; Perani D
    Neurobiol Aging; 2013 Nov; 34(11):2694.e13-8. PubMed ID: 23820589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study.
    Shinotoh H; Namba H; Fukushi K; Nagatsuka S; Tanaka N; Aotsuka A; Ota T; Tanada S; Irie T
    Ann Neurol; 2000 Aug; 48(2):194-200. PubMed ID: 10939570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease.
    Kuhl DE; Koeppe RA; Minoshima S; Snyder SE; Ficaro EP; Foster NL; Frey KA; Kilbourn MR
    Neurology; 1999 Mar; 52(4):691-9. PubMed ID: 10078712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age.
    Namba H; Iyo M; Fukushi K; Shinotoh H; Nagatsuka S; Suhara T; Sudo Y; Suzuki K; Irie T
    Eur J Nucl Med; 1999 Feb; 26(2):135-43. PubMed ID: 9933347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
    Richter N; Beckers N; Onur OA; Dietlein M; Tittgemeyer M; Kracht L; Neumaier B; Fink GR; Kukolja J
    Brain; 2018 Mar; 141(3):903-915. PubMed ID: 29309600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET.
    Shinotoh H; Aotsuka A; Fukushi K; Nagatsuka S; Tanaka N; Ota T; Tanada S; Irie T
    Neurology; 2001 Feb; 56(3):408-10. PubMed ID: 11171913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. White matter lesions and the cholinergic deficit in aging and mild cognitive impairment.
    Richter N; Michel A; Onur OA; Kracht L; Dietlein M; Tittgemeyer M; Neumaier B; Fink GR; Kukolja J
    Neurobiol Aging; 2017 May; 53():27-35. PubMed ID: 28208063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.